DDInter1256 DDInter1676
A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Nafcillin {u} (Compound) resembles {v} (Compound) Flucloxacillin
Nafcillin {u} (Compound) resembles {v} (Compound) Mezlocillin
Nafcillin {u} (Compound) binds {v} (Gene) SLC22A6
Nafcillin {u} (Compound) upregulates {v} (Gene) SATB1
Nafcillin {u} (Compound) is included by {v} (Pharmacologic Class) Penicillins
Nafcillin {u} (Compound) downregulates {v} (Gene) COPS7A
Nafcillin {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Nafcillin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Nafcillin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clarithromycin
Nafcillin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixabepilone
Nafcillin (Compound) resembles Flucloxacillin (Compound)
Nafcillin (Compound) resembles Mezlocillin (Compound)
Nafcillin (Compound) binds SLC22A6 (Gene)
Nafcillin (Compound) upregulates SATB1 (Gene)
Nafcillin (Compound) is included by Penicillins (Pharmacologic Class)
Nafcillin (Compound) downregulates COPS7A (Gene)
Nafcillin (Compound) causes Gastrointestinal disorder (Side Effect)
Nafcillin may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Nafcillin may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone